New cocktail of cancer drugs shows promise in early leukemia trial
NCT ID NCT04872790
First seen Feb 14, 2026 · Last updated Jun 21, 2026 · Updated 20 times
Summary
This early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when combined with other drugs like dasatinib and prednisone. The main goal is to check for side effects, but researchers will also look at how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIXED PHENOTYPE ACUTE LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax (a BCL-2 inhibitor) combined with dasatinib, prednisone, rituximab, and blinatumomab
What this could lead to
If successful, this could lead to a more effective treatment option for Philadelphia chromosome-positive acute lymphoblastic leukemia, potentially improving remission rates.
What could go wrong
This is a very early (Phase 1) trial with only 20 participants, focused on finding the right dose and checking safety. It is too small to prove effectiveness, and side effects from the drug combination are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.